We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ATyr Pharma is laying off 30% of its staff and otherwise cutting its costs in response to lackluster data. The biotech made the cuts after preclinical data on its anticancer antibodies suggested they lack the required efficacy.